ST-segment elevation myocardial infarction: Difference between revisions
(Created page with "==Diagnosis== (1) ≥ 1-mm (0.1mV) ST-segment elevation in at least 2 anatomically contiguous limb leads (aVL to III, including -aVR) (2) ≥ 1-mm ST-segment elevation in a pr...") |
No edit summary |
||
| Line 1: | Line 1: | ||
==Diagnosis== | ==Diagnosis== | ||
#≥ 1-mm (0.1mV) ST-segment elevation in at least 2 anatomically contiguous limb leads (aVL to III, including -aVR) | |||
#≥ 1-mm ST-segment elevation in a precordial lead V4 through V6 | |||
#≥ 2-mm (0.2mV) ST-segment elevation in V1 through V3 | |||
#a new left bundle branch block | |||
ACC/AHA, ESC | |||
==DDx== | ==DDx== | ||
#Myocardial ischemia or infarction | |||
#Noninfarction, transmural ischemia (Prinzmetal's angina pattern or acute takotsubo cardiomyopathy) | |||
#Acute myocardial infarction (MI) | |||
#Post-MI (ventricular aneurysm pattern)-Previous MI with recurrent ischemia in the same area-Acute pericarditis-Normal "early repolarization variants" | |||
#Left ventricular hypertrophy or left bundle branch block (only V1-V2 or V3)-Myocarditis (may look like myocardial infarction or pericarditis) | |||
#Brugada patterns (V1-V3 with right bundle branch block-appearing morphology) | |||
#Myocardial tumor | |||
#Myocardial trauma | |||
#Hyperkalemia (only leads V1 and V2) | |||
#Hypothermia (J wave/Osborn wave) | |||
==Treatment== | |||
===Adjunctive=== | |||
#O2 | |||
#ASA 162, 325chewable PO or 600mg PR; Plavix 300 or 600mg if ASA allergy | |||
#NTG | |||
#Morphine | |||
#BBlocker: | |||
##PO within 24 hours | |||
##IV beta-blocker is reasonable for patients who are hypertensive in the absence of: | |||
###signs of heart failure | |||
###evidence of a low cardiac output state | |||
###post beta-blocker cardiogenic shock risk factors (age > 70 years, systolic blood pressure < 120 mm Hg, sinus tachycardia > 110 bpm or heart rate < 60 bpm, increased time since onset of symptoms of STEMI) | |||
###other relative contraindications to beta blockade (PR interval > 0.24 s, second- or third-degree heart block, active asthma, or reactive airway disease) | |||
O2 | |||
ASA 162, 325chewable PO or 600mg PR; Plavix 300 or 600mg if ASA allergy | |||
NTG | |||
Morphine | |||
BBlocker: | |||
===Anticoagulants=== | ===Anticoagulants=== | ||
#Heparin (UFH) | |||
##Bolus 60U/kg (max: 4000U) | |||
Heparin (UFH) | ##12U/kg/h (max: 1000U/h) | ||
##NB: monitor PTT: 50-70s | |||
#LMWH | |||
##<75yo with serum Cr < 2.5 mg/dL (men) or < 2.0 mg/dL (women): | |||
###30mg IV bolus, followed by 1mg/kg SC q12h | |||
##≥ 75yo: 0.75-mg/kg SC q12h | |||
NB: monitor PTT: 50-70s | ##CrCl < 30 mL/min: 1mg/kg SC qd | ||
##NB: note renal clearance | |||
#Fondaparinux | |||
##Cr < 3.0 mg/dL: 2.5mg IV bolus, then 2.5-mg SC qd, started 24 hr after bolus | |||
LMWH | ##NB: monitor anti-Xa levels | ||
#Bivalirudin | |||
<75yo with serum Cr < 2.5 mg/dL (men) or < 2.0 mg/dL (women): | ##0.75-mg/kg IV bolus, followed by 1.75 mg/kg/h | ||
##CrCl < 30 mL/min: 0.75-mg/kg IV bolus, followed by 1.0 mg/kg/h | |||
≥ 75yo: 0.75-mg/kg SC q12h | |||
CrCl < 30 mL/min: 1mg/kg SC qd | |||
NB: note renal clearance | |||
Fondaparinux | |||
NB: monitor anti-Xa levels | |||
Bivalirudin | |||
===Antiplatelet=== | ===Antiplatelet=== | ||
#GPIIB/IIIa Inhibitors: Abciximab (ReoPro®), Eptifibatide (Integrilin®), Tirofiban (Aggrastat®) | |||
##Given right before PCI | |||
GPIIB/IIIa Inhibitors: Abciximab (ReoPro®), Eptifibatide (Integrilin®), Tirofiban (Aggrastat®) | ##Defer to cardiologist | ||
#Clopidogrel (Plavix®) | |||
##300mg po x1 (onset 2h, peak 6-15h) | |||
##600mg po x1 (faster onset) | |||
Clopidogrel (Plavix®) | |||
==Definitive== | ==Definitive== | ||
Fibrinolytics within 30mins | Fibrinolytics within 30mins | ||
| Line 138: | Line 64: | ||
PCI within 90mins | PCI within 90mins | ||
==Source == | ==Source == | ||
DONALDSON (adapted from ACC/AHA Practice Guidelines 2004/5), EBM 6/09 | DONALDSON (adapted from ACC/AHA Practice Guidelines 2004/5), EBM 6/09 | ||
[[Category:Cards]] | [[Category:Cards]] | ||
Revision as of 16:54, 12 March 2011
Diagnosis
- ≥ 1-mm (0.1mV) ST-segment elevation in at least 2 anatomically contiguous limb leads (aVL to III, including -aVR)
- ≥ 1-mm ST-segment elevation in a precordial lead V4 through V6
- ≥ 2-mm (0.2mV) ST-segment elevation in V1 through V3
- a new left bundle branch block
ACC/AHA, ESC
DDx
- Myocardial ischemia or infarction
- Noninfarction, transmural ischemia (Prinzmetal's angina pattern or acute takotsubo cardiomyopathy)
- Acute myocardial infarction (MI)
- Post-MI (ventricular aneurysm pattern)-Previous MI with recurrent ischemia in the same area-Acute pericarditis-Normal "early repolarization variants"
- Left ventricular hypertrophy or left bundle branch block (only V1-V2 or V3)-Myocarditis (may look like myocardial infarction or pericarditis)
- Brugada patterns (V1-V3 with right bundle branch block-appearing morphology)
- Myocardial tumor
- Myocardial trauma
- Hyperkalemia (only leads V1 and V2)
- Hypothermia (J wave/Osborn wave)
Treatment
Adjunctive
- O2
- ASA 162, 325chewable PO or 600mg PR; Plavix 300 or 600mg if ASA allergy
- NTG
- Morphine
- BBlocker:
- PO within 24 hours
- IV beta-blocker is reasonable for patients who are hypertensive in the absence of:
- signs of heart failure
- evidence of a low cardiac output state
- post beta-blocker cardiogenic shock risk factors (age > 70 years, systolic blood pressure < 120 mm Hg, sinus tachycardia > 110 bpm or heart rate < 60 bpm, increased time since onset of symptoms of STEMI)
- other relative contraindications to beta blockade (PR interval > 0.24 s, second- or third-degree heart block, active asthma, or reactive airway disease)
Anticoagulants
- Heparin (UFH)
- Bolus 60U/kg (max: 4000U)
- 12U/kg/h (max: 1000U/h)
- NB: monitor PTT: 50-70s
- LMWH
- <75yo with serum Cr < 2.5 mg/dL (men) or < 2.0 mg/dL (women):
- 30mg IV bolus, followed by 1mg/kg SC q12h
- ≥ 75yo: 0.75-mg/kg SC q12h
- CrCl < 30 mL/min: 1mg/kg SC qd
- NB: note renal clearance
- <75yo with serum Cr < 2.5 mg/dL (men) or < 2.0 mg/dL (women):
- Fondaparinux
- Cr < 3.0 mg/dL: 2.5mg IV bolus, then 2.5-mg SC qd, started 24 hr after bolus
- NB: monitor anti-Xa levels
- Bivalirudin
- 0.75-mg/kg IV bolus, followed by 1.75 mg/kg/h
- CrCl < 30 mL/min: 0.75-mg/kg IV bolus, followed by 1.0 mg/kg/h
Antiplatelet
- GPIIB/IIIa Inhibitors: Abciximab (ReoPro®), Eptifibatide (Integrilin®), Tirofiban (Aggrastat®)
- Given right before PCI
- Defer to cardiologist
- Clopidogrel (Plavix®)
- 300mg po x1 (onset 2h, peak 6-15h)
- 600mg po x1 (faster onset)
Definitive
Fibrinolytics within 30mins
OR
PCI within 90mins
Source
DONALDSON (adapted from ACC/AHA Practice Guidelines 2004/5), EBM 6/09
